Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly encountered in routine clinical practice, particularly among patients with obesity, type 2 diabetes, and cardiometabolic risk factors. While many patients have a relatively benign course, the presence of advanced fibrosis is associated with substantially worse hepatic and extrahepatic outcomes. Early identification of patients at increased fibrosis risk is therefore essential to guide further evaluation and management. Here is a quick question on evidence-based risk stratification in MASLD! (Scroll down to answer the question) ##Reference## Lai JCT, et al.
Noninvasive tests for liver fibrosis in 2024. Clin Mol Hepatol. 2024;30(Suppl):S187-S208.## ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no warranties,…
